Head-to-head evidence
BAT1706 vs HLX04
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline
BAT1706 · Avzivi
Marketed by Bio-Thera Solutions
NCT03329911 · Phase 3 · completed
The trial was randomized, double-blind, and actively controlled, with 651 participants, and used a clinical tumor-response endpoint assessed by RECIST 1.1. However, the week-18 primary endpoint comparison is unclear because only response counts are posted and no statistical analysis is reported.
HLX04
Developed by Shanghai Henlius Biotech
NCT03952403 · Phase 3 · status unknown
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The first listed primary outcome for this study is Part 1 safety and tolerability; the survival figures shown here are the Part 2 primary endpoint (progression-free survival) and the overall-survival secondary endpoint from the final analysis.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BAT1706's landscape · HLX04's landscape